Overview

• The research team reports a distinctive 3D‑genomic DNA‑folding signature in blood that distinguishes people with ME/CFS from healthy controls using Oxford BioDynamics’ EpiSwitch technology.
• Authors cite about 92% sensitivity and 98% specificity in their analysis of patient and control samples.
• Findings highlight immune and inflammation pathways that researchers say could guide future treatment research.
• The study was a proof‑of‑concept with a relatively small cohort skewed toward severely affected, housebound patients and used healthy rather than disease‑matched controls, which experts note could confound results.
• ME/CFS affects roughly 400,000 people in the UK and is currently diagnosed by exclusion on the NHS, so a validated biomarker test could shorten delays and improve access to care.